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The neuropeptide AgRP promotes food intake and weight gain by antagonizing signaling at melanocortin 3 and 4 receptors
in the brain, but the limited phenotype of mice lacking AgRP raised questions about its importance. Four recent studies
addressed this by creating mice in which AgRP neurons, which also express NPY and GABA, are ablated postnatally, and
although details vary, they suggest that AgRP neurons are more essential to feeding and weight gain than is AgRP itself.
A recent paper in Cell Metabolism (Wortley et al., 2005) indicates that AgRP itself is important for feeding and weight
gain, but only as mice age, and the mechanism may involve dysfunction of the thyroid axis.In complex physiologic systems, the true role of a regulatory
molecule may sometimes be difficult to ascertain, with different
experimental paradigms suggesting different views of the mole-
cule’s position in physiology and disease. This may vary even
within a specific circuit, where the role of individual components
may be defined with different degrees of clarity. This is well illus-
trated within themelanocortin circuit for regulation of energy ho-
meostasis. Melanocortin 4 receptor (MC4R) signaling plays an
unambiguous role in determining anorexigenic and catabolic
physiology, as revealed by both genetics and pharmacology,
using both gain- and loss-of-function approaches (Huszar
et al., 1997; Cone, 1999). In contrast, the precise physiologic
role of the neuropeptide AgRP, which antagonizes signaling at
both the MC4R and MC3R, has been more difficult to define.
MC4Rs on hypothalamic neurons receive both agonistic and
antagonistic signals. a-melanocyte-stimulating hormone (a-
MSH) derived from the POMCgene product stimulates these re-
ceptors and suppresses food intake and induces weight loss
(Fan et al., 1997). In contrast, AgRP is an endogenous antago-
nist of the MC4R produced in neurons that coexpress NPY,
and it promotes food intake and positive energy balance (Oll-
mann et al., 1997; Rossi et al., 1998). This anabolic role is dem-
onstrated by central administration of AgRP or genetic overex-
pression, which reduce the MC4R signal and thereby induce
hyperphagia, anabolism, and obesity. It was therefore a surprise
to many in the field that loss of function of AgRP via knockout of
the AgRP gene in mice produced a bland metabolic phenotype,
with normal body weight, adiposity, and food intake, raising the
possibility that this neuropeptide was not as essential for energy
homeostasis as initially suspected (Qian et al., 2002). A series of
recent papers have been published, one in the December issue
of Cell Metabolism (Wortley et al., 2005), that address this ques-
tion and provide several promising avenues for future research.
When genetic loss of function produces a phenotype that dif-
fers from pharmacology, a number of possible explanations
must be considered. Prominent among these is that gene abla-
tion in early development promotes compensatory mechanisms
that override the loss of the gene in question. Although much in-
voked, the specifics of such putative mechanisms have rarely
been defined with precision. Four papers published recentlyCELL METABOLISM 3, 83–85, FEBRUARY 2006 ª2006 ELSEVIER INC.have taken the approach of genetically ablating not the AgRP
peptide but the neurons that normally make the peptide and
conclude that loss of AgRP neurons produces a more robust
phenotype than loss of AgRP alone, with hypophagia and lean-
ness and a variety of other features (Figure 1).
Three different approaches were used to selectively target
AgRP neurons for death, all using genetic approaches permit-
ting faithful expression of specific molecules in this restricted
group of cells. These approaches involved (1) transgenic ex-
pression of the neurotoxic CAG expanded repeat form of
ataxin-3, which induces cell death (Bewick et al., 2005); (2)
cre-mediated deletion of the mitochondrial transcription factor
A (Tfam), which results in progressive postnatal cell death (Xu
et al., 2005); and (3) expression of the receptor for diphtheria
toxin in AgRP neurons, permitting temporally controlled ablation
of these neurons after administration of diphtheria toxin (Gropp
et al., 2005; Luquet et al., 2005). In one study (Bewick et al.,
2005), mice with reduced numbers of AgRP neurons (which
also express NPY) have reduced body weight, body fat, and
food intake. In another (Xu et al., 2005), the reduction in body
weight was more modest, and only evident in females. Whether
the differences in these phenotypes results from differing neuro-
nal loss, or other factors, is not yet apparent. In two studies in
which loss of AgRP neurons was selectively induced postnatally
via injection of diphtheria toxin (Gropp et al., 2005; Luquet et al.,
2005), hypophagia and weight loss were seen, but the implica-
tions of the two studies are somewhat different. In both studies
postnatal ablation of the AgRP neurons caused acute suppres-
sion of feeding over several days, in one case leading to impend-
ing starvation (Luquet et al., 2005). The study of Luquet et al. has
an additional important dimension, by examining the effect of
cell ablation at two different ages (Luquet et al., 2005). Ablation
of AgRP neurons in the early postnatal period was equally effec-
tive at ablating the neurons as was the toxin administration in
adults, but neonatal ablation was entirely without effect on feed-
ing or body weight, indicating that some form of compensation
was operating that was possible only at young ages (Luquet
et al., 2005). The nature of this compensation is as yet unknown.
The above studies permit several conclusions to be drawn.
First, we are reminded that the function of a neuron expressingDOI 10.1016/j.cmet.2006.01.003 83
M I N I R E V I E WFigure 1. The consequences of loss of AgRP or AgRP neurons
A)Hypothalamic neurons expressingMC4Rs receive antagonistic signals that act on this receptor the agonist a-MSH arises fromPOMC neurons, and the antagonist AgRP
arises from neurons coexpressing AgRP and NPY. Stimulation of MC4Rs evokes catabolic signals that reduce appetite and promote weight loss. In prior studies, gene
knockout of AgRP produced a minimal phenotype. Genetic ablation of AgRP neurons, however, produces a phenotype of leanness, which could be a consequence of
loss of NPY, GABA, or some as yet undiscovered product of this neuron, as well as loss of AgRP. When these neurons are ablated in very young mice, an unknown com-
pensation occurs that permits animals to feed and regulate weight normally.
B)When older mice with AgRP (peptide) knockout are studied, they are lean, due not to reduced feeding but to increased thyroid hormones, which increase metabolic rate.
Prior studies demonstrated that melanocortin signaling regulates activity of TRH neurons in the paraventricular nucleus that control the thyroid axis. AgRP suppresses the
thyroid axis by antagonizing melanocortin signals on the TRH neuron, and removal of AgRP is hypothesized to activate the axis. Why this occurs only in older animals is
unknown.a specific neuropeptide such as AgRP is not limited to the re-
lease of that neuropeptide. For example, hypothalamic AgRP
neurons also express NPY and the neurotransmitter GABA
(Backberg et al., 2003), and potentially other undiscovered mol-
ecules, whose actions may be critical to the function of the neu-
ron in a physiologic circuit. For this reason, the consequences of
deleting a neuron may be quite different in magnitude (or even
direction) from the consequences of deleting the specific neuro-
peptide. Second, the apparent capacity of the immature brain to
respond to neuronal loss with a network-wide compensation is
truly impressive. Identification of the signals that initiate the
compensation and the cellular targets that effect it will likely
produce exciting new insights into the mechanisms for brain
plasticity, as well as potential new mediators of energy balance
regulation.
An additional aspect of the ‘‘normal phenotype’’ of AgRP
knockout mice is revealed in the paper by Wortley et al. (Wortley
et al., 2005). Unlike the above studies, it did not employ fancy
genetic approaches to ablating AgRP neurons as an approach
to this question. Rather, these investigators studied AgRP
knockout mice more extensively than earlier studies, including
an assessment of the effects of AgRP loss in older animals. Their
younger mice had minimal phenotypes largely concordant with
the earlier studies. One exception was their observation of
reduced compensatory feeding after starvation, a subtle but im-
portant finding also made in mice with deletion of NPY (Segal-
Lieberman et al., 2003). However, overt leanness, which was
absent in younger mice, was observed in older mice (6 months).
Interestingly, this leanness was not ascribed to reduced food
intake but rather to increased energy expenditure, apparently
associated with increased activity of the thyroid axis (Figure 1).
Although the lack of hypophagia as an explanation may be sur-
prising, the overactivity of the thyroid axis with loss of AgRP is
not entirely unexpected.84Suppression of the thyroid axis in response to food restriction
has been well studied (Ahima et al., 1996; Legradi et al., 1997;
Kim et al., 2000; Flier et al., 2000; Fekete et al., 2002; Lechan
and Fekete, 2005), and roles for both falling leptin and the mel-
anocortin axis are well described as bringing this about. AgRP,
which increases with starvation, has been shown to suppress
expression of the neuropeptide TRH in the paraventricular nu-
cleus, which then suppresses pituitary TSH and thyroid hor-
mones. Removal of AgRP (and subsequent increased MC4R
tone) might then be expected to derepress TRH, driving TSH
and thyroid hormones to increased levels. If this sequence is
true, it might imply that negative regulation of TRH by thyroid
hormone, a dominant influence in this system,might be inhibited
if MC4R tone is too high, a testable hypothesis. It may be tempt-
ing to speculate that the common development of obesity with
aging is linked, via reduced MC4R tone, to subtle suppression
of the thyroid axis, in addition to the expected stimulation of
food intake and suppression of energy expenditure by reduced
sympathetic activity. However much more data will be neces-
sary before we can invoke melanocortin-regulated changes in
thyroid thermogenesis as being important influences over en-
ergy balance and obesity with aging or other situations.
So what can we say, in the light of all of these studies, about
the ‘‘real role’’ of AgRP in energy balance? Excess AgRP is suf-
ficient to cause obesity, as has been known since the initial dis-
covery of this gene (Ollmann et al., 1997). In contrast, loss of
AgRP, or AgRP neurons, in young animals is surprisingly benign,
owing to compensatory mechanisms of uncertain nature that
provide more than adequate protection for loss of AgRP and
AgRP neuron-induced feeding and anabolism. Ablation of
AgRP peptide promotes leanness, but this is seen primarily as
mice age, at least in part through activation of the thyroid axis
and consequent increases in energy expenditure. Finally, loss
of AgRP neurons in adults is extremely poorly tolerated, causingCELL METABOLISM : FEBRUARY 2006
M I N I R E V I E Wprofound suppression of the capacity to feed, proving the es-
sential role of these neurons in orexigenic drive (Figure 1).
What remains to be determined is to what degree the hypopha-
gia and leanness due to loss of these neurons in adults is due to
loss of AgRP, as opposed to other factors released by these
neurons, both known (NPY and GABA) and unknown. Until we
have this information, the ‘‘real role’’ of AgRP, as opposed to
the AgRP/NPY/GABA/?X neurons that expresses it, will remain
a subject of continued investigation and speculation. And
whether altered expression of AgRP, or altered numbers of
AgRP neurons, are important contributors to the variations in
body weight in human populations will likewise require further
study.
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